Embera NeuroTherapeutics Forms Clinical Development Collaboration with Exponential Pharma Ventures

Clinical Development of Embera’s Cocaine Dependence Therapeutic – EMB 001C—is planned through pharmaceutical partnership

SHREVEPORT, La.--()--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company. Exponential Pharma Ventures, a company specialized in development of early stage biomedical technology through pharmaceutical partnerships, is seeking a partner to advance Embera’s lead product, EMB-001C into phase 2a clinical trials. The pharmaceutical partner will receive an option to license and commercialize the product after clinical proof of concept. Embera and Exponential have already initiated discussions with prospective partners. EMB-001C is a combination drug product that has recently demonstrated preliminary clinical proof of concept in a randomized, double-blind, placebo–controlled pilot study in cocaine-dependent human subjects.

Bob Linke, CEO of Embera stated: “Exponential Pharma presents a compelling opportunity to collaborate with a pharmaceutical partner in a capital-efficient structure, which we believe is an optimal way to advance this combination drug to human proof of concept.” Mike Webb, Managing Director of Exponential Pharma Ventures commented, “We are tremendously excited by EMB-001C’s potential to help the large number of cocaine-dependent patients who currently have no effective therapies to help them break free.”

Embera’s technology has also demonstrated preclinical proof of concept in animal models for methamphetamine and nicotine dependence. The combination drug approach was developed by Embera’s Chief Scientific Officer, Dr. Nicholas Goeders, and represents an innovative and proprietary treatment paradigm for the illicit drug dependence field and other indications. Dr. Goeders explained: “As our dual mechanism broadly targets the craving associated with all addictions, we believe the drug combination may also prove useful in other dependence disorders such as nicotine in smoking cessation and alcohol dependence.”

Bob Linke, CEO of Embera, added: “The fact that EMB-001C is a proprietary combination of two off-patent, FDA-approved drugs, with a history of use in patients over decades, should positively impact the clinical development for this combination drug. The unmet medical need in cocaine dependence and the novel treatment paradigm of EMB-001C, we believe, can meet the Fast Track designation requirements of the FDA.”

About the Company

Embera NeuroTherapeutics, Inc. is a specialty pharmaceutical company founded in 2005 to develop and commercialize novel treatments for addiction and obesity - significant, growing problems in the United States and worldwide for which there are limited effective drug therapies. Embera is developing a patent-pending drug combination, targeting specific brain functions related to the neurobiology of addiction. The company’s lead product, EMB-001, is based on technology licensed from Louisiana State University and developed by the company’s Chief Scientific Officer, Dr. Nicholas Goeders, Head of the Department of Pharmacology, Toxicology and Neuroscience at Louisiana State University Health Sciences Center, Shreveport. Dr. Goeders has been a recipient of NIH funding to support studies of drug dependence and stress for over twenty-five years and has authored over eighty scientific publications on this subject. By targeting two neurological mechanisms associated with addiction, EMB-001 may affect the neurobiology of addiction, including the brain functions of craving and loss of control, rather than blocking or mimicking the effect of the abused drug, as most treatment approaches do today. The company has been funded by several venture capital funds, including Louisiana Fund I and Louisiana Ventures, LP (managed by Barrett, Vernon & Montgomery LLC). For additional information about the company, please visit www.emberaneuro.com.

About Exponential Pharma Ventures

Exponential Pharma Ventures was established to create new business enterprises or partnerships with commercial pharmaceutical companies to efficiently develop novel early-stage biomedical technologies. The company leverages proprietary operating deal-making experience to match entrepreneurs, technologists, managers, contract research partners and investors. Because Exponential works collaboratively with pharmaceutical partners from partnership formation through clinical proof-of-concept, the result is a focused and efficient collaboration that quickly translates new science to the clinic, effectively responding to both needs of entrepreneurs and the companies that eventually market the biopharmaceutical products. For more information, visit www.exrxventures.com

Contacts

Embera NeuroTherapeutics, Inc.
Bob Linke, 617-719-9406
President and CEO
rlinke@emberaneuro.com
or
Exponential Pharma Ventures LLC
Fred Meyer, PhD, CFA, 617-340-3244
Managing Director
fmeyer@exrxventures.com

Release Summary

Embera NeuroTherapeutics collaborates with Exponential Pharma Ventures to develop a pharmaceutical partnership for clinical development of a cocaine dependence therapeutic.

Contacts

Embera NeuroTherapeutics, Inc.
Bob Linke, 617-719-9406
President and CEO
rlinke@emberaneuro.com
or
Exponential Pharma Ventures LLC
Fred Meyer, PhD, CFA, 617-340-3244
Managing Director
fmeyer@exrxventures.com